Curated News
By: NewsRamp Editorial Staff
February 25, 2025
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
Discuss on Reddit
LinkedIn
Substack
Telegram
GithubTLDR
- iTOL-102, a potential cure for diabetes, is an innovative collaboration with promising results and transformative implications.
- iTOL-102 combines IsletRx cells with iTOL-100 to potentially cure Type 1 Diabetes by inducing immune tolerance.
- iTOL-102 could eliminate chronic immunosuppression for diabetes patients, offering a breakthrough in treatment and potentially improving quality of life.
- iTOL-102's functional insulin release and disease reversal in animal models demonstrate exciting potential for a novel diabetes treatment approach.
Impact - Why it Matters
This news signifies a potentially transformative step in diabetes treatment, paving the way towards the potential development of iTOL-100 and requesting regulatory approvals for commercialization of a potential cure for type 1 diabetes.
Summary
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) and Kadimastem Ltd., in collaboration with iTolerance Inc., announced the result from the Type B pre-IND meeting with the FDA, regarding the development of iTOL-102, a potential cure for diabetes. iTOL-102 consists of Kadimastem’s allogenic human stem cell-derived pancreatic islets (IsletRx cells) combined with iTolerance’s immunomodulator (iTOL-100).
Kadimastem and iTolerance believe that the completion of the pre-IND meeting is a significant milestone toward the clinical development of iTOL-102, funded in part by grants received from the Israel-U.S. Binational Industrial Research and Development Foundation.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
